Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report) – Investment analysts at HC Wainwright dropped their Q1 2026 earnings estimates for Viridian Therapeutics in a research note issued to investors on Monday, March 30th. HC Wainwright analyst D. Tsao now expects that the company will post earnings of ($1.16) per share for the quarter, down from their prior forecast of ($1.11). HC Wainwright has a “Buy” rating and a $22.00 price objective on the stock. The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($4.03) per share. HC Wainwright also issued estimates for Viridian Therapeutics’ Q2 2026 earnings at ($1.22) EPS, Q4 2026 earnings at ($1.17) EPS and FY2026 earnings at ($4.75) EPS.
VRDN has been the subject of several other reports. Royal Bank Of Canada reduced their price target on Viridian Therapeutics from $45.00 to $42.00 and set an “outperform” rating for the company in a research note on Friday, February 27th. The Goldman Sachs Group lowered their price objective on Viridian Therapeutics from $41.00 to $36.00 and set a “buy” rating on the stock in a research report on Tuesday. Evercore reissued an “outperform” rating and set a $44.00 target price on shares of Viridian Therapeutics in a report on Tuesday, January 20th. Wall Street Zen downgraded shares of Viridian Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Finally, UBS Group assumed coverage on shares of Viridian Therapeutics in a research report on Wednesday, January 7th. They set a “buy” rating and a $50.00 price target on the stock. Thirteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Viridian Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $39.21.
Viridian Therapeutics Price Performance
Viridian Therapeutics stock opened at $18.84 on Wednesday. The company has a market capitalization of $1.93 billion, a price-to-earnings ratio of -5.73 and a beta of 1.16. The company has a current ratio of 12.65, a quick ratio of 12.65 and a debt-to-equity ratio of 0.08. Viridian Therapeutics has a 12 month low of $9.90 and a 12 month high of $34.29. The stock’s 50 day moving average is $28.63 and its 200-day moving average is $27.77.
Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) last posted its earnings results on Thursday, February 26th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.18). Viridian Therapeutics had a negative return on equity of 83.25% and a negative net margin of 483.57%.The company had revenue of $0.13 million for the quarter, compared to analyst estimates of $15.75 million.
Hedge Funds Weigh In On Viridian Therapeutics
A number of hedge funds have recently added to or reduced their stakes in VRDN. Perceptive Advisors LLC lifted its position in shares of Viridian Therapeutics by 108.1% during the 4th quarter. Perceptive Advisors LLC now owns 3,042,703 shares of the company’s stock valued at $94,689,000 after acquiring an additional 1,580,303 shares during the period. Morgan Stanley increased its position in shares of Viridian Therapeutics by 805.6% in the fourth quarter. Morgan Stanley now owns 1,738,225 shares of the company’s stock worth $54,094,000 after purchasing an additional 1,546,284 shares during the period. Avoro Capital Advisors LLC bought a new position in shares of Viridian Therapeutics in the fourth quarter worth $46,680,000. Vanguard Group Inc. raised its stake in Viridian Therapeutics by 29.6% in the fourth quarter. Vanguard Group Inc. now owns 5,612,144 shares of the company’s stock valued at $174,650,000 after purchasing an additional 1,280,161 shares in the last quarter. Finally, Commodore Capital LP raised its stake in Viridian Therapeutics by 35.4% in the second quarter. Commodore Capital LP now owns 4,875,000 shares of the company’s stock valued at $68,152,000 after purchasing an additional 1,275,000 shares in the last quarter.
Key Stories Impacting Viridian Therapeutics
Here are the key news stories impacting Viridian Therapeutics this week:
- Positive Sentiment: Topline REVEAL-1 Phase III results reported clinical activity for elegrobart — supports the drug’s efficacy and preserves an approval/commercial pathway, which is a material long-term positive for VRDN. Viridian Therapeutics, Inc. (VRDN) Discusses Positive Topline Results from Elegrobart REVEAL-1 Phase III Trial in Active Thyroid Eye Disease Transcript
- Positive Sentiment: Some analysts remain constructive on longer-term upside: HC Wainwright maintains a Buy and has modeled recovery into FY2029–2030 (including a FY2030 EPS projection), reflecting belief in commercial potential beyond near-term noise. (Market commentary / analyst note summaries)
- Neutral Sentiment: Short-term trading has been volatile — the stock saw large swings on volume as the market digested nuanced efficacy/market-position takeaways; that raises short-term uncertainty but also increases liquidity for active traders. Viridian Therapeutics (VRDN) Soars 5.6%: Is Further Upside Left in the Stock?
- Negative Sentiment: Market reaction included a sharp pre-market drop (reported ~41% at one point) as investors judged the results insufficiently dominant versus competitors and priced in execution/market-share risk. VRDN stock plummeted 41% pre-market today — what did its phase 3 active thyroid eye disease trial reveal?
- Negative Sentiment: Several firms lowered expectations/targets after the readout: Goldman cut its price target, Wells Fargo trimmed its target to $20, and other notes signaled more cautious near-term forecasts — increasing near-term downside risk from analyst-driven flows. The Goldman Sachs Group Lowers Viridian Therapeutics (NASDAQ:VRDN) Price Target to $36.00 Wells Fargo & Company Lowers Viridian Therapeutics (NASDAQ:VRDN) Price Target to $20.00 Wedbush Has Lowered Expectations for Viridian Therapeutics (NASDAQ:VRDN) Stock Price
- Negative Sentiment: Critical takes emphasize that REVEAL-1 returned clinically meaningful but not clearly market-dominant data, which may limit peak sales vs. competitors and lengthen the commercialization ramp — a negative for near- to medium-term valuation. Viridian’s REVEAL-1: Clinically Active But Not Market-Dominating, Shares React Badly
About Viridian Therapeutics
Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.
In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.
Further Reading
Receive News & Ratings for Viridian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viridian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
